Leadership Team
Dr Ronald Shnier
Non-Executive Chairman
Dr Ronald Shnier completed a radiology fellowship at Royal Prince Alfred Hospital (RPAH) before undertaking his neuroradiology fellowship at RPAH in 1989 and musculoskeletal fellowship at the University of California Los Angeles (UCLA) in 1991. He was a consultant specialist at RPAH between 1990 and 1993. Dr Shnier started one of Australia’s first Private MRI practices in 1991 before becoming General Manager of Mayne’s Diagnostic Imaging in 2007 and was its National Director for many years. He has served on several international MRI advisory boards. Dr Shnier has a strong involvement in clinical research, and has lectured both in Australia and overseas.
Mr Maurie Stang
Non-Executive Deputy Chairman
Mr Maurie Stang has more than three decades of experience building and managing companies in the healthcare and biotechnology industry in Australia and internationally. His strong business development and marketing skills have resulted in the successful commercialisation of intellectual property across global markets.
Dr Susan Pond
Non-Executive Director
Dr Susan Pond AM (MD, DSc, FRACP) has a strong scientific and commercial background, having held executive positions in the biotechnology and pharmaceutical industry for 12 years, including as Chairman and Managing Director of Johnson & Johnson Research Pty Limited (2003 to 2009). Dr Pond has held many Board positions such as: Non-Executive Director and Chairman of AusBiotech Limited (2006 to 2008); Director of the Australian Nuclear Science and Technology Organisation (ANSTO) (2010 to 2014); Board member of Innovation Australia (2012 to 2015); and Vice President of the Academy of Technological Sciences and Engineering (ATSE) (2010 to 2015). She is a Fellow of ATSE, the Australian Institute of Company Directors, and the Academy of Health and Medical Sciences. Dr Pond obtained specialist clinical credentials in internal medicine, clinical pharmacology and clinical toxicology, and held academic appointments at the University of California in San Francisco and the University of Queensland before joining industry.
Mr Robert Waring
Company Secretary
Mr Robert Waring (BEc, CA, FCIS, FFin, FAICD) has over 50 years of experience in financial and corporate roles, including over 30 years in Company Secretarial roles for ASX-listed companies, and over 20 years as a Director of ASX-listed companies. Mr Waring has significant company secretarial experience for both listed and unlisted companies, and is currently serving as Company Secretary for ASX-listed companies Aeris Environmental Ltd and Xref Limited. He is a Director of Oakhill Hamilton Pty Ltd, which provides secretarial and corporate advisory services to a range of listed and unlisted companies.
Dr Ivan Rajkovic
Interim Chief Technology Officer
Dr Ivan Rajkovic (BSc, MPhil, PhD, FIPTA) has over 17 years of experience in biomedical research, in both academic and commercial settings. His career comprised over 13 years post-doctoral academic research, and a further four years of commercial research and development, in the field of genetic engineering and bio-pharmaceuticals. Dr Rajkovic’s particular technical expertise lies in the areas of molecular immunology and oncology, biomolecular engineering, transgenics, gene therapy, microbial biochemistry, diagnostics and pharmaceuticals. He is an author of 45 publications in peer-reviewed scientific journals and books in the fields of molecular and cellular biology and immunology. Dr Rajkovic was a partner in a major Sydney-based intellectual property firm for 14 years. Since his retirement from the partnership, Dr Rajkovic has been advising a number of companies in the life sciences field on patent portfolio structuring, patent filing strategies and portfolio management.
Dr Karen Duggan - Founder
Dr Karen Duggan was a founder of the Company, and the Executive Director and Chief Executive Officer from September 2006 until May 2024. She was formerly director of the Hypertension Service – South Western Sydney Area Health Service (SWSAHS), and was a past Chair of the National Blood Pressure and Vascular Disease Advisory Committee. Dr Duggan was also a member of the Cardiovascular Health Advisory Committee of the National Heart Foundation of Australia, the Post-Acute Stroke Guidelines Advisory Committee of the Australian Government Department of Health and Aging, and the Cardiovascular Clinical Expert Reference Group of the NSW Department of Health. In Dr Duggan’s role as Director of the Hypertension Service SWSAHS she was responsible for managing a multidisciplinary team (medical, nursing, laboratory and administrative staff), as well as developing and implementing new and innovative strategies in patient care within SWSAHS. The Hypertension Service participated in a number of clinical trials of both new therapeutics as well as evaluation of new diagnostic devices. It was with great sadness and regret that Vectus announced the death of Dr Duggan. Dr Duggan expressed her desire to see the technologies that she helped pioneer utilised for the benefit of humanity. She was a visionary, a world-leading Nephrologist and a Research Scientist of outstanding talent who contributed to cardiovascular science and medicine.
